Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have received an average rating of “Hold” from the five ...
C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals ...
On Monday, C4 Therapeutics Inc (CCCC) stock saw a modest uptick, ending the day at $6.45 which represents a slight increase of $0.84 or 14.97% from the prior close of $5.61. The stock opened at $5.58 ...
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...
Oct. 15, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...
C4 Therapeutics (CCCC) announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback